These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. HIV/HCV co-infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article. Petrovic LM. Liver Int; 2007 Jun; 27(5):598-606. PubMed ID: 17498243 [Abstract] [Full Text] [Related]
3. The epidemiology and natural history of HIV/HBV and HIV/HCV co-infections. Mathews G, Bhagani S. J HIV Ther; 2003 Nov; 8(4):77-84. PubMed ID: 14671504 [Abstract] [Full Text] [Related]
4. [Management of HCV-HIV patients]. Pol S, Cacoub P, Pialoux G, Benhamou Y, Halfon P, Rosenthal E, Perronne C. Gastroenterol Clin Biol; 2007 Nov; 31(8-9 Pt 3):4S7-12. PubMed ID: 17965629 [Abstract] [Full Text] [Related]
6. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Macías J, Mira JA, López-Cortés LF, Santos I, Girón-González JA, González-Serrano M, Merino D, Hernández-Quero J, Rivero A, Merchante N, Trastoy M, Carrillo-Gómez R, Arizcorreta-Yarza A, Gómez-Mateos J, Pineda JA. Antivir Ther; 2006 Nov; 11(7):839-46. PubMed ID: 17302246 [Abstract] [Full Text] [Related]
8. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. AIDS; 2006 May 12; 20(8):1171-9. PubMed ID: 16691069 [Abstract] [Full Text] [Related]
9. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, Rodriguez-Novoa S, Alvarez E, Jimenez-Nacher I, Soriano V. J Antimicrob Chemother; 2010 Mar 12; 65(3):543-7. PubMed ID: 20032006 [Abstract] [Full Text] [Related]
11. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. Cooper CL, Mills E, Angel JB. AIDS; 2007 Jan 02; 21(1):71-6. PubMed ID: 17148970 [Abstract] [Full Text] [Related]
12. Influence of viral hepatitis on HIV infection. Rockstroh JK. J Hepatol; 2006 Jan 02; 44(1 Suppl):S25-7. PubMed ID: 16338020 [Abstract] [Full Text] [Related]
16. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database. Petoumenos K, Ringland C, Australian HIV Observational Database. HIV Med; 2005 May 02; 6(3):155-63. PubMed ID: 15876281 [Abstract] [Full Text] [Related]
17. [Coinfection with HIV and HCV--epidemiologic, diagnostic, clinical and therapeutic implications]. Jabłonowska E. Przegl Epidemiol; 2004 May 02; 58(4):621-8. PubMed ID: 15810503 [Abstract] [Full Text] [Related]
18. Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines in human immunodeficiency virus-1-infected individuals. Tornero C, Alberola J, Tamarit A, Navarro D. Clin Microbiol Infect; 2006 Jun 02; 12(6):555-60. PubMed ID: 16700705 [Abstract] [Full Text] [Related]
19. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, Shakil O, Fung JJ. Liver Transpl; 2003 Mar 02; 9(3):239-47. PubMed ID: 12619020 [Abstract] [Full Text] [Related]
20. Liver histopathology in human immunodeficiency virus-hepatitis C virus co-infected patients with fatal liver disease. Lichterfeld M, Haas S, Fischer HP, Voigt E, Rockstroh JK, Spengler U. J Gastroenterol Hepatol; 2005 May 02; 20(5):739-45. PubMed ID: 15853988 [Abstract] [Full Text] [Related] Page: [Next] [New Search]